[11] B.R. Huang, T.S. Chen, D.T. Bau, I.C. Chuang, C.F. Tsai, P.C. Chang, D.Y. Lu, EGFR is a pivotal
regulator of thrombin-mediated inflammation in primary human nucleus pulposus culture, Sci. Rep.,
7 (2017) 8578.
[12] W. Li, Q. Fang, P. Zhong, L. Chen, L. Wang, Y. Zhang, J. Wang, X. Li, Y. Wang, J. Wang, G. Liang,
EGFR Inhibition Blocks Palmitic Acid-induced inflammation in cardiomyocytes and Prevents
Hyperlipidemia-induced Cardiac Injury in Mice, Sci. Rep., 6 (2016) 24580.
[13] W.S. Qu, D.S. Tian, Z.B. Guo, J. Fang, Q. Zhang, Z.Y. Yu, M.J. Xie, H.Q. Zhang, J.G. Lu, W. Wang,
Inhibition of EGFR/MAPK signaling reduces microglial inflammatory response and the associated
secondary damage in rats after spinal cord injury, J. Neuroinflammation., 9 (2012) 178.
[14] N. Fujiwara, K. Kobayashi, Macrophages in inflammation, Curr. Drug Targets Inflamm. Allergy, 4
(2005) 281-286.
[15] A.M. Mulenos, Y. Sun, A. Kalinowski, J.O. Joerns, M. Haslip, E. D'Amico, B. Clark, J.L. Koff, Novel
Role of Epidermal Growth Factor Receptor in Macrophages, in: B36. Macrophages: Basic and
Translational Studies, American Thoracic Society, 2017, pp. A3274-A3274.
[16] D.M. Hardbower, K. Singh, M. Asim, T.G. Verriere, D. Olivares-Villagomez, D.P. Barry, M.M.
Allaman, M.K. Washington, R.M. Peek, Jr., M.B. Piazuelo, K.T. Wilson, EGFR regulates macrophage
activation and function in bacterial infection, J. Clin. Invest., 126 (2016) 3296-3312.
[17] L. Zeboudj, A. Giraud, L. Guyonnet, Y. Zhang, L. Laurans, B. Esposito, J. Vilar, A. Chipont, N.
Papac-Milicevic, C.J. Binder, A. Tedgui, Z. Mallat, P.L. Tharaux, H. Ait-Oufella, Selective EGFR
(Epidermal Growth Factor Receptor) Deletion in Myeloid Cells Limits Atherosclerosis-Brief Report,
Arterioscler. Thromb. Vasc. Biol., 38 (2018) 114-119.
[18] L. Wang, Z. Huang, W. Huang, X. Chen, P. Shan, P. Zhong, Z. Khan, J. Wang, Q. Fang, G. Liang, Y.
Wang, Inhibition of epidermal growth factor receptor attenuates atherosclerosis via decreasing
inflammation and oxidative stress, Sci. Rep., 8 (2017) 45917.
[19] S.R. Johnston, A. Leary, Lapatinib: a novel EGFR/HER2 tyrosine kinase inhibitor for cancer, Drugs
Today, 42 (2006) 441-453.
[20] A. Martin-Kohler, J. Widmer, G. Bold, T. Meyer, U. Séquin, P. Traxler, Furo[2,3-d]pyrimidines and
Oxazolo[5,4-d]pyrimidines as Inhibitors of Receptor Tyrosine Kinases (RTK), Helv. Chim. Acta, 87
(2004) 956-975.
[21] R. Lin, S.G. Johnson, P.J. Connolly, S.K. Wetter, E. Binnun, T.V. Hughes, W.V. Murray, N.B.
Pandey, S.J. Moreno-Mazza, M. Adams, A.R. Fuentes-Pesquera, S.A. Middleton, Synthesis and
evaluation of 2,7-diamino-thiazolo[4,5-d] pyrimidine analogues as anti-tumor epidermal growth
factor receptor (EGFR) tyrosine kinase inhibitors, Bioorg. Med. Chem. Lett., 19 (2009) 2333-2337.
[22] A. Elkamhawy, S. Paik, A.H.E. Hassan, Y.S. Lee, E.J. Roh, Hit discovery of 4-amino-N-(4-(3-
(trifluoromethyl)phenoxy)pyrimidin-5-yl)benzamide: A novel EGFR inhibitor from a designed small
library, Bioorg. Chem., 75 (2017) 393-405.
[23] J.N. Sharma, A. Al-Omran, S.S. Parvathy, Role of nitric oxide in inflammatory diseases,
Inflammopharmacology, 15 (2007) 252-259.
[24] L.F. S., P.K. P., H.I. N., K. S., H. H., B. S., H.J. M., G.M. B., Role of nitric oxide in inflammation, Acta
Physiol. Scand., 173 (2001) 113-118.
[25] C.R. Lyons, The Role of Nitric Oxide in Inflammation, in: F.J. Dixon (Ed.) Advances in
Immunology, Academic Press, 1995, pp. 323-371.
[26] M.W. Pijnenburg, J.C. De Jongste, Exhaled nitric oxide in childhood asthma: a review, Clin. Exp.
Allergy, 38 (2008) 246-259.
[27] V. Pravettoni, C. Incorvaia, F. Frati, Role of measurement of nitric oxide in respiratory diseases,
Recenti. Prog. Med., 99 (2008) 258-262.
[28] A.Z. El-Hashim, M.A. Khajah, W.M. Renno, R.S. Babyson, M. Uddin, I.F. Benter, C. Ezeamuzie, S.
Akhtar, Src-dependent EGFR transactivation regulates lung inflammation via downstream signaling
involving ERK1/2, PI3Kdelta/Akt and NFkappaB induction in a murine asthma model, Sci. Rep., 7
(2017) 9919.